201
Participants
Start Date
May 1, 2019
Primary Completion Date
March 10, 2021
Study Completion Date
March 15, 2022
GeneSight Psychotropic test
GeneSight® Psychotropic powered by CPGx® technology, the only test for depression reimbursable by Medicaid and Medicare. GeneSight® is a neuropsychiatric, combinatorial, PGx test that provides recommendations for psychotropic medications (antidepressants, mood stabilizers, hypnotics for insomnia, and antipsychotics) based on a patient's individual genetic profile.
Canadian Network for Mood and Anxiety Treatment (CANMAT) Best Practice Guidelines
Guidelines for treatment
Massachusetts General Hospital, Boston
Collaborators (2)
Genetic Alliance
OTHER
Patient-Centered Outcomes Research Institute
OTHER
Vanderbilt University
OTHER
Montefiore Medical Center
OTHER
Louisiana State University Health Sciences Center in New Orleans
OTHER
Duke University
OTHER
University of North Carolina, Chapel Hill
OTHER
Massachusetts General Hospital
OTHER